Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Southwest Chemie

    Southwest Chemie is specialized in first aid products, especially of use in burns caused by corrosive chemicals such as HF acid, sulphuric acid, and caustic alkalis in the chemi

  • No Image
    Sovereign Pharma Pvt Ltd

    Sovereign Pharma Pvt Ltd was incorporated in 2003, is engaged in the manufacturing of liquid formulations on a contract basis ? either Loan License (LL) or Product-to-Product (

  • No Image
    SPIC Ltd

    SPIC (EPC) offers wide range of Engineering services to clients in the field of Oil and Gas, Petrochemical and Chemical sectors. Has the capacity to do Engineering for complete